Retrospective analysis of complete pathological response in locally advanced HER2 positive breast cancer patients treated with neoadjuvant chemotherapy associated to trastuzumab at Brazilian National Cancer Institute

被引：0
|
作者：
Nunes, A. S. [1 ]
Goncalves, A. [1 ]
Ominelli, J. [1 ]
Costa, S. [1 ]
机构：
[1] Inst Nacl Canc INCA, HC 3, Rio De Janeiro, Brazil
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
105P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Complete pathological response in patients with locally advanced cancer of breast and positive Her2/neu with neoadjuvant chemotherapy
    Heidy Cedeño
    Rafael Araúz
    Fernando Cebamanos
    Idalmis de Torraza
    Ana Porcell
    [J]. BMC Cancer, 7 (Suppl 1)
  • [2] Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
    Huyen Thi Phung
    Hoa Thi Nguyen
    Tung Van Nguyen
    Tai Van Nguyen
    Lan Anh Thi Dinh
    Chu Van Nguyen
    [J]. BREAST CANCER-TARGETS AND THERAPY, 2020, 12 : 117 - 122
  • [3] Complete pathological response in patients with HER2 positive breast cancer treated with neoadjuvant therapy in Colombia
    Rodriguez, Mauricio
    Gonzalez, Diego M.
    El-Sharkawy, Farah
    Castano, Mileny
    Madrid, Jorge
    [J]. BIOMEDICA, 2023, 43 (03): : 396 - 405
  • [4] Pathological complete response in HER2 positive breast cancer treated with trastuzumab and chemotherapy: Predictive factors report.
    Cudos, Ariadna Gasol
    Morales, Serafin
    Alvarez, Anna Novell
    Lopez, Anna Serrate
    Sanchez, Ana Velasco
    Salvia, Antonieta Salud
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Pathological complete response with neoadjuvant (NA) chemotherapy (trastuzumab (T) and docetaxel (D)) in HER2 positive (3+) locally advanced (LA) breast cancer (BC) patients.
    Moluçon, C
    Vanlemmens, L
    Chollet, P
    Weber, B
    Beal, D
    Mayer, F
    Benoit, L
    Zanetta, S
    Mery-Mignard, D
    Vasseur, B
    Arnould, L
    Coudert, B
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S59 - S59
  • [6] Neoadjuvant trastuzumab in HER2-positive breast cancer, is pathological complete response enough?
    Ruvalcaba-Limon, Eva
    Pozo-Romero, Mariela
    Bautista-Pina, Veronica
    Tenorio-Torres, Alberto
    Morales-Vazquez, Flavia
    Rodriguez-Cuevas, Sergio
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : 342 - 344
  • [7] Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
    Patel, A. B.
    Sharma, M.
    Joga, S.
    Goel, S.
    Doval, D. C.
    Talwar, V.
    Goyal, S.
    Batra, U.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1481 - S1482
  • [8] Pathological complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER2 amplification in locally advanced breast cancer.
    Arnould, L.
    Gelly-Marty, M.
    Couturier, J.
    Ferrant, E.
    Callier, P.
    Ettore, F.
    Sagan, C.
    Antoine, M.
    Penault-Llorca, F.
    Fumoleau, P.
    Coudert, B.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S49 - S49
  • [9] Role of HER2 FISH ratios in predicting pathological complete response (pCR) to neoadjuvant systemic chemotherapy with trastuzumab in patients with inflammatory breast cancer (IBC) and non-inflammatory locally advanced breast cancer
    Kogawa, T.
    Fouad, T.
    Liu, D.
    Shen, Y.
    Masuda, H.
    Mac Gregor, M. Chavez
    Alvarez, R.
    Valero, V.
    Hortobagyi, G.
    Ueno, N.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S418 - S419
  • [10] Usefulness of neoadjuvant chemotherapy in patients with luminal HER2(-) locally advanced breast cancer
    Kim, H. S.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
12345